Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822925 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3GRM2 | |
| SCHEMBL900719 | 0.83 | NR1H2 (0.58) | NR1H2NR1H3CNR1CNR2MDM2 | |
| SCHEMBL21555501 | 0.78 | HSD11B1 (0.41) | GRM2 | |
| SCHEMBL1271771 | 0.73 | NR1H2 (0.47) | NR1H2NR1H3MEN1KMT2A | |
| SCHEMBL6272353 | 0.72 | ALDH1A1 (0.44) | HCAR1MAPK1HTTMEN1KMT2A | |
| SCHEMBL30248988 | 0.72 | PARP1 (0.54) | MAPK1MEN1KMT2A | |
| SCHEMBL12900966 | 0.72 | NR1H2 (0.74) | NR1H2NR1H3 | |
| SCHEMBL1271026 | 0.71 | NR1H2 (0.56) | NR1H2NR1H3HTTMEN1KMT2A | |
| SCHEMBL1272181 | 0.71 | NR1H2 (0.56) | NR1H2NR1H3MAPK1 | |
| SCHEMBL1272108 | 0.71 | NR1H2 (0.52) | NR1H2NR1H3CNR1CNR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | disclosed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4211230-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4041725-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021223359-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021223705-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| EP-3874030-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2021-09-08 | — | — | EP | disclosed |
| EP-3523290-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-3397756-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018059549-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
| EP-3233918-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017114497-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2017-07-06 | — | — | WO | disclosed |
| WO-2016100882-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |